COTI-2 is primarily investigated for its potential in cancer therapy, particularly targeting cancers that are resistant to conventional treatments. It functions by inhibiting specific pathways involved in cancer cell survival and proliferation, making it a promising candidate for treating various types of malignancies. Researchers are exploring its efficacy in preclinical and clinical studies, focusing on its ability to enhance the effectiveness of existing therapies or serve as a standalone treatment. Its application is particularly relevant in cases where traditional chemotherapy has failed, offering hope for improved outcomes in difficult-to-treat cancers.